- Home
- STRO vs SRZN Comparison
STRO vs SRZN Comparison
Compare STRO & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- SRZN
- Stock Information
- Founded
- STRO 2003
- SRZN 2015
- Country
- STRO United States
- SRZN United States
- Employees
- STRO N/A
- SRZN N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- STRO Health Care
- SRZN Health Care
- Exchange
- STRO Nasdaq
- SRZN Nasdaq
- Market Cap
- STRO 77.7M
- SRZN 72.8M
- IPO Year
- STRO 2018
- SRZN N/A
- Fundamental
- Price
- STRO $0.88
- SRZN $9.39
- Analyst Decision
- STRO Hold
- SRZN Strong Buy
- Analyst Count
- STRO 7
- SRZN 2
- Target Price
- STRO $3.97
- SRZN $38.50
- AVG Volume (30 Days)
- STRO 513.9K
- SRZN 9.4K
- Earning Date
- STRO 08-12-2025
- SRZN 08-11-2025
- Dividend Yield
- STRO N/A
- SRZN N/A
- EPS Growth
- STRO N/A
- SRZN N/A
- EPS
- STRO N/A
- SRZN N/A
- Revenue
- STRO $66,434,000.00
- SRZN $11,638,000.00
- Revenue This Year
- STRO N/A
- SRZN N/A
- Revenue Next Year
- STRO N/A
- SRZN N/A
- P/E Ratio
- STRO N/A
- SRZN N/A
- Revenue Growth
- STRO N/A
- SRZN N/A
- 52 Week Low
- STRO $0.52
- SRZN $5.90
- 52 Week High
- STRO $5.17
- SRZN $27.75
- Technical
- Relative Strength Index (RSI)
- STRO 57.66
- SRZN 62.73
- Support Level
- STRO $0.83
- SRZN $8.20
- Resistance Level
- STRO $1.01
- SRZN $9.50
- Average True Range (ATR)
- STRO 0.07
- SRZN 0.52
- MACD
- STRO 0.01
- SRZN 0.10
- Stochastic Oscillator
- STRO 51.67
- SRZN 91.30
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).